Market Overview

2018 Report Package on Immuno-Oncology: Inhibitory & Stimulatory Immunomodulators -


The "Report
Package Immuno-Oncology: Inhibitory and Stimulatory Immunomodulators"

report has been added to's

This product consists of four reports in pdf format describing the
competitive field of new molecular entities directed against inibitory
as well stimulatory immune checkpoints on T-cells, antigen presenting
cells (APCs)/dendritic cells or tumor cells and against
immunosuppressive factors in the tumor microencironment, including Treg
cells, tumor-associated macrophages (TAM), myeloid derived suppressor
cells (MDSC).

More than 190 unique molecules (many antibodies) targeting inhibitory
and stimulatory immunomodulators are in clinical development as
monotherapy or in combination with other checkpoint modulators or
targeted cancer therapeutics. This number has more than doubled since
December 2016.

The reports include compilations of currently active projects in
research and development of immunomodulators in immuno-oncology. In
addition, each report lists company-specific R&D pipelines of cancer

Competitor projects are listed in a tabular format providing
information on:

  • Drug Codes
  • Target / Mechanism of Action
  • Class of Compound
  • Company
  • Product Category
  • Indication
  • R&D Stage
  • Additional comments with a hyperlink leading to the source of

Reports Included

Report 1: PD-1 and PD-L1 Immune Checkpoint Inhibitors 2018

1a) PD-1 Receptor Antagonists

1b) PD-L1 Inhibitors

2) Corporate PD-1 and PD-L1 Checkpoint Inhibitor R&D Pipelines

Report 2: CTLA-4, LAG-3, TIM-3, TIGIT & Other Immune Checkpoint
Inhibitors 2018

1a) CTLA-4 Receptor Antagonists

1b) LAG-3 Antagonists

1c) TIM-3 Antagonists

1d) TIGIT Antagonists

1e) Other Inhibitors of Negative Immune Checkpoints

2) Corporate Inhibitors of Negative Immune Checkpoints R&D Pipelines

Report 3: CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune
Checkpoint Activators

1) Corporate Immune Checkpoint Activator R&D Pipelines

Report 4: Tumor Microenvironment Modulation via IDO, TGF-,
CXCR4, CSF-1R, CD47-SIRP, adenosine pathway & STING 2018

1a) IDO & TDO Inhibitors

1b) TGF-beta Inhibitors

1c) CXCR4 Antagonists & CXCL2/SDF-1 Inhibitors

1d) Novel Chemokine Inhibitors & Chemokine Receptor Antagonists

1e) CSF-1R Antagonists & CSF-1 Inhibitors

1f) CD47 Antagonists & SIRPalpha Inhibitors

1g) Adenosine Pathway Modulation

1h) STING Agonists

2) Corporate Tumor Microenvironment Modulator R&D Pipelines

For more information about this report visit

View Comments and Join the Discussion!